Sutrisna E
J Clin Diagn Res. 2017; 10(11):FE01-FE03.
PMID: 28050398
PMC: 5198351.
DOI: 10.7860/JCDR/2016/21067.8914.
Ogawa R, Stachnik J, Echizen H
Clin Pharmacokinet. 2014; 53(12):1083-114.
PMID: 25248847
DOI: 10.1007/s40262-014-0189-3.
Yim E, Kang H, Jung J, Sohn S, Cho S
Asia Pac Allergy. 2013; 3(4):231-40.
PMID: 24260728
PMC: 3826610.
DOI: 10.5415/apallergy.2013.3.4.231.
Niki Y, Itokawa K, Okazaki O
Antimicrob Agents Chemother. 1998; 42(7):1751-5.
PMID: 9661016
PMC: 105678.
DOI: 10.1128/AAC.42.7.1751.
Bayar C, Ozer I
Eur J Drug Metab Pharmacokinet. 1998; 22(4):415-9.
PMID: 9512943
DOI: 10.1007/BF03190979.
Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.
Sato J, Nakata H, OWADA E, Kikuta T, Umetsu M, Ito K
Eur J Clin Pharmacol. 1993; 44(3):295-8.
PMID: 8491248
DOI: 10.1007/BF00271376.
Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.
Troger U, Meyer F
Clin Pharmacokinet. 1995; 28(4):287-314.
PMID: 7648758
DOI: 10.2165/00003088-199528040-00003.
Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha H, Chen J, Freiburghaus A, Follath F
Br J Clin Pharmacol. 1995; 39(3):321-6.
PMID: 7619675
PMC: 1365010.
DOI: 10.1111/j.1365-2125.1995.tb04455.x.
Pharmacokinetics of sustained release theophylline in low and high multidose regimens.
Koeter G, Jonkman J, de Vries K, Schoenmaker R, Greving J, de Zeeuw R
Br J Clin Pharmacol. 1981; 12(5):647-51.
PMID: 7332728
PMC: 1401956.
DOI: 10.1111/j.1365-2125.1981.tb01283.x.
Theophylline pharmacokinetics in advanced age.
Antal E, Kramer P, Mercik S, Chapron D, LAWSON I
Br J Clin Pharmacol. 1981; 12(5):637-45.
PMID: 7332727
PMC: 1401974.
DOI: 10.1111/j.1365-2125.1981.tb01282.x.
Measurement of excretion characteristics of theophylline and its major metabolites.
Jonkman J, Tang D, Upton R, RIEGELMAN S
Eur J Clin Pharmacol. 1981; 20(6):435-41.
PMID: 7286053
DOI: 10.1007/BF00542096.
Comparative pharmacokinetics of theophylline and aminophylline in man.
Aslaksen A, Bakke O, Vigander T
Br J Clin Pharmacol. 1981; 11(3):269-73.
PMID: 7213528
PMC: 1401615.
DOI: 10.1111/j.1365-2125.1981.tb00533.x.
Urine flow-dependence of theophylline renal clearance in man.
Tang-Liu D, Tozer T, RIEGELMAN S
J Pharmacokinet Biopharm. 1982; 10(4):351-64.
PMID: 7153869
DOI: 10.1007/BF01065168.
Pharmacokinetics of theophylline: a dose-range study.
Rovei V, CHANOINE F, Strolin Benedetti M
Br J Clin Pharmacol. 1982; 14(6):769-78.
PMID: 7150456
PMC: 1427546.
DOI: 10.1111/j.1365-2125.1982.tb02035.x.
Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose.
Horai Y, Ishizaki T, Sasaki T, Watanabe M, KABE J
Eur J Clin Pharmacol. 1982; 23(2):111-21.
PMID: 7140800
DOI: 10.1007/BF00545964.
Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
Birkett D, Miners J, Attwood J
Br J Clin Pharmacol. 1983; 15(5):567-9.
PMID: 6860533
PMC: 1427728.
DOI: 10.1111/j.1365-2125.1983.tb02093.x.
Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid.
Birkett D, Miners J, Attwood J
Br J Clin Pharmacol. 1983; 15(1):117-9.
PMID: 6849735
PMC: 1427820.
DOI: 10.1111/j.1365-2125.1983.tb01475.x.
Non-linear elimination processes of theophylline.
Gundert-Remy U, Hildebrandt R, Hengen N, Weber E
Eur J Clin Pharmacol. 1983; 24(1):71-8.
PMID: 6832205
DOI: 10.1007/BF00613930.
Differential effects of cimetidine on theophylline metabolic pathways.
Grygiel J, Miners J, Drew R, Birkett D
Eur J Clin Pharmacol. 1984; 26(3):335-40.
PMID: 6734695
DOI: 10.1007/BF00548764.
Influence of chronic dosing on theophylline clearance.
Efthimiou H, Morgan D, Raymond K, McLean A
Br J Clin Pharmacol. 1984; 17(5):525-30.
PMID: 6733000
PMC: 1463460.
DOI: 10.1111/j.1365-2125.1984.tb02385.x.